The U.S. Preventive Services Task Force has issued a final recommendation statement and evidence summary upholding its earlier recommendation against use of hormone therapy for the primary prevention of chronic conditions in postmenopausal women.
A randomized clinical trial conducted in the United States and three other countries compared self-administered isoniazid and rifapentine with and without weekly reminders to directly observed therapy (DOT). Self-administered therapy without reminders was non-inferior to DOT in the United States; no other comparisons met non-inferiority criteria.
The most notable new recommendation of the updated hospital-acquired pneumonia/ventilator-associated pneumonia guideline may be its endorsement of limiting the duration of antibiotic therapy to seven days in most cases.
By 2020, more than 50 million U.S. women will be older than 51, the mean age when menopause occurs. Despite the availability of effective hormonal and nonhormonal treatments for menopausal symptoms, few women with menopausal symptoms are evaluated or treated, reports a new scientific perspective.
Although potential benefit may have been detected in a post hoc subset analysis, the addition of anidulafungin in the initial phase of primary treatment of suspected or documented invasive aspergillosis was not associated with a significant improvement in survival.